ArticleTissue engineering. Part A2011
Developing vasculature and stroma in engineered human myocardium.
Article in Tissue engineering. Part A, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 62 citations in OpenAlex.
- Topological Tracks Patterned via 3D Printing Vascularize Murine Organ-Scale Constructs.Cell biomaterials · 2026Article
- Bioprinted platform for parallelized screening of engineered microtissues in vivo.Cell stem cell · 2025Article
- Organotypic stromal cells impact endothelial cell transcriptome in 3D microvessel networks.Scientific reports · 2022Article
- Engineering the multiscale complexity of vascular networks.Nature reviews. Materials · 2022Review
- Cardiac mechanostructure: Using mechanics and anisotropy as inspiration for developing epicardial therapies in treating myocardial infarction.Bioactive materials · 2021Review
- Targeting HIF-α for robust prevascularization of human cardiac organoids.Journal of tissue engineering and regenerative medicine · 2021Article
- Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling.Frontiers in cardiovascular medicine · 2021Review
- Cardiac Tissue Engineering: Inclusion of Non-cardiomyocytes for Enhanced Features.Frontiers in cell and developmental biology · 2021Review
- Bioprintability: Physiomechanical and Biological Requirements of Materials for 3D Bioprinting Processes.Polymers · 2020Review
- Creation of a contractile biomaterial from a decellularized spinach leaf without ECM protein coating: An in vitro study.Journal of biomedical materials research. Part A · 2020Article
- Engineered human myocardium with local release of angiogenic proteins improves vascularization and cardiac function in injured rat hearts.Biomaterials · 2020Article
- New Strategies to Enhance Myocardial Regeneration: Expectations and Challenges from Preclinical Evidence.Current stem cell research & therapy · 2020Review
- Human Cardiac Fibroblast Number and Activation State Modulate Electromechanical Function of hiPSC-Cardiomyocytes in Engineered Myocardium.Stem cells international · 2020Article
- Versican-A Critical Extracellular Matrix Regulator of Immunity and Inflammation.Frontiers in immunology · 2020Review
- Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction.Nature communications · 2019Article
- Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes.ACS biomaterials science & engineering · 2019Article
- A New Era of Cardiac Cell Therapy: Opportunities and Challenges.Advanced healthcare materials · 2019Review
- Generation of pancreatic β cells for treatment of diabetes: advances and challenges.Stem cell research & therapy · 2018Review
- A role for proteoglycans in vascular disease.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- Activation of the unfolded protein response downregulates cardiac ion channels in human induced pluripotent stem cell-derived cardiomyocytes.Journal of molecular and cellular cardiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
We recently developed a scaffold-free patch of human myocardium with human embryonic stem cell-derived cardiomyocytes and showed that stromal and endothelial cells form vascular networks in vitro and improve cardiomyocyte engraftment. Here, we hypothesize that stromal cells regulate the angiogenic phenotype by modulating the extracellular matrix (ECM). Human marrow stromal cells (hMSCs) support the greatest degree of endothelial cell organization, at 1.3- to 2.4-fold higher than other stromal cells tested. Stromal cells produce abundant ECM components in patches, including fibrillar collagen, hyaluronan, and versican. We identified two clonal hMSC lines that supported endothelial networks poorly and robustly. Interestingly, the pro-angiogenic hMSCs express high levels of versican, a chondroitin sulfate proteglycan that modulates angiogenesis and wound healing, whereas poorly angiogenic hMSCs produce little versican. When transplanted onto uninjured athymic rat hearts, patches with proangiogenic hMSCs develop ~ 50-fold more human vessels and form anastomoses with the host circulation, resulting in chimeric vessels containing erythrocytes. Thus, stromal cells play a key role in supporting vascularization of engineered human myocardium. Different stromal cell types vary widely in their proangiogenic ability, likely due in part to differences in ECM synthesis. Comparison of these cells defines an in vitro predictive platform for studying vascular development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.